Samir Acharya
President & CEO
Samir is an accomplished pharmaceutical executive with over a decade of work experience in various areas of the pharmaceutical industry. Samir began his pharma career at Trent Drugs (Wholesale) Ltd, learning the pharmaceutical distribution business from the ground up working in the warehouse.
Following graduation from Queen’s University in 2001 he left Canada for Basel, Switzerland to do cancer research for Hoffman La-Roche at their head office. His work there led to a publication in the Archives of Biochemistry and Biophysics.
After returning from Switzerland he re-joined Trent Drugs working in sales and operations. He was promoted to increasingly senior positions including Director of Business Development. When Trent Drugs was purchased by AmerisourceBergen he was promoted to Vice President, Health Systems. During his tenure at Trent/AmerisourceBergen he opened up the company’s distribution to the hospital segment, negotiated agreements with tier one manufacturers and hospital group purchasing organizations and grew the revenue into hospitals by over $30 million. Samir’s science background also afforded him the responsibility of the quality department for Trent’s 7 distribution centres where he successfully managed multiple Health Canada GMP and Narcotic Inspections.
Samir joined SteriMax Inc. in 2006 as Executive Vice President overseeing business development and sales/marketing activities, including in/out licensing, acquisitions, product launches, as well as management of key stakeholders. Since then, the company has grown from 4 people and 12 products to 100 people and 90 + products and is now one of the top sterile injectable companies in Canada.
In 2020, he assumed the role of President.
Samir holds a Bachelor of Science (Honours) in Biochemistry from Queen’s University.